Complex generics, proprietary products to drive growth: Dr. Reddy’s Laboratories
New Delhi: Dr. Reddy’s Laboratories Ltd expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward.
“Our growth, going forward, will be driven by the attractive pipeline of complex generics as well as our new proprietary products,” Dr Reddy’s Laboratories chairman K. Satish Reddy said in a message in the company’s latest annual report.
The company will leverage these across the markets we operate in, together with increasing our OTC (over-the-counter) portfolio, he added.
Highlighting the road map the company is taking for expansion, Reddy said, “We are creating a branded generics platform in North America and expanding our biologics play in Russia, CIS (Commonwealth of Independent States) and other emerging markets”.
The outlook for the API (active pharmaceutical ingredient) business is also positive, he added. A branded generic is a drug that is a bio-equivalent to the original product, but is now marketed under another company’s brand name.
During fiscal 2016, the company’s revenues from North America for generics grew 19% to Rs.7,540 crore. “The sustained performance of our injectables franchise and market share gains in key molecules were the main reason,” Reddy said.